This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ . Medical treatment of advanced testicular cancer. JAMA 2008; 299: 672–684.
Necchi A, Lanza F, Rosti G, Martino M, Fare E, Pedrazzoli P . High-dose chemotherapy for germ cell tumors: do we have a model? Expert Opin Biol Ther 2015; 15: 33–44.
Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R . High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340–348.
Kondagunta GV, Bacik J, Sheinfeld J, Bajorin D, Bains M, Reich L et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007; 25: 85–90.
International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594–603.
Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010; 28: 4906–4911.
Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002; 20: 1864–1873.
De Giorgi U, Rosti G, Slavin S, Yaniv I, Harousseau JL, Ladenstein R et al. Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours. Br J Cancer 2005; 93: 412–417.
Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28: 1706–1713.
Reddy Ammakkanavar N, Matei D, Abonour R, Einhorn LH . High-dose chemotherapy for recurrent ovarian germ cell tumors. J Clin Oncol 2015; 33: 226–227.
Meisel JL, Woo KM, Sudarsan N, Eng J, Patil S, Jacobsen EP et al. Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecol Oncol 2015; 138: 566–572.
Voss MH, Feldman DR, Motzer RJ . High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. Expert Rev Anticancer Ther 2011; 11: 1091–1103.
Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25: 247–256.
Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16: 1152–1159.
Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007; 25: 2778–2784.
The authors declare no conflict of interest.
About this article
Cite this article
DeFilipp, Z., Rosand, C., Goldstein, D. et al. Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors. Bone Marrow Transplant 52, 132–134 (2017). https://doi.org/10.1038/bmt.2016.189